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DObjective: Mitral valve annuloplasty and mitral valve replacement are common strategies for the manage-
ment of functional ischemic mitral regurgitation with ischemic cardiomyopathy. However, mitral valve annu-
loplasty may create some degree of functional mitral stenosis. The purpose of this study was to compare the
mitral valve hemodynamics in patients with functional ischemic mitral regurgitation undergoing mitral valve
annuloplasty or mitral valve replacement, using exercise echocardiography.
Methods: We performed resting and exercise echocardiography in 70 patients matched for indexed effective
orifice area, systolic pulmonary arterial pressure, and left ventricular ejection fraction after mitral valve annu-
loplasty or mitral valve replacement with coronary artery bypass grafting.
Results: There was no significant difference between the 2 groups regarding baseline demographic and
clinical data. Exercise systolic pulmonary arterial pressure was higher in the mitral valve annuloplasty
group compared with the mitral valve replacement group (from 36.3  8.1 mm Hg to 55  12 mm Hg,
vs mitral valve replacement: 33  6 mm Hg to 42  6.2 mm Hg, P ¼ .0001). Exercise-induced
improvement in effective orifice area and indexed effective orifice area was better in the mitral valve
replacement group (mitral valve replacement: þ0.23  0.04 vs mitral valve annuloplasty: 0.1  0.09
cm2, P ¼ .001, for effective orifice area; mitral valve replacement: þ0.14  0.03 vs mitral valve annulo-
plasty: 0.04  0.07 cm2/m2, P ¼ .03, for indexed effective orifice area). Exercise indexed effective
orifice area was correlated with exercise systolic pulmonary arterial pressure (r ¼ 0.45; P ¼ .01). In
a multivariable analysis mitral valve annuloplasty, postoperative indexed effective orifice area and resting
mitral peak gradients were independent predictors of elevated systolic pulmonary arterial pressure during
exercise.
Conclusions: In patients with functional ischemic mitral regurgitation, mitral valve annuloplasty may cause
functional mitral stenosis, especially during exercise. Mitral valve annuloplasty was associated with poor
exercise mitral hemodynamic performance, lack of mitral valve opening reserve, and markedly elevated
postoperative exercise systolic pulmonary arterial pressure compared with mitral valve replacement. (J Thorac
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Functional ischemic mitral regurgitation (FIMR) is associ-
ated with poor outcome, and its best management remains
controversial.1-3 Mitral valve annuloplasty (MVA) and
mitral valve replacement (MVR) combined with coronary
artery bypass grafting represent the most common
surgical strategies.
The rationale of restrictive MVA is to reduce the mitral
annulus by shortening the anteroposterior distance with a
prosthetic ring selected 2 sizes below the measured inter-
trigonal length.4 Recent studies suggest that MVA may
create some degree of postoperative functional mitralrdiovascular Surgery c Volume 148, Number 2 447
Abbreviations and Acronyms
AUC ¼ area under the curve
EOA ¼ effective orifice area
FIMR ¼ functional ischemic mitral regurgitation
IEOA ¼ indexed effective orifice area
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
LVOT ¼ left ventricular outflow tract
MR ¼ mitral regurgitation
MVA ¼ mitral valve annuloplasty
MVR ¼ mitral valve replacement
PH ¼ pulmonary hypertension
SD ¼ standard deviation
SPAP ¼ systolic pulmonary arterial pressure
SV ¼ stroke volume
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Dstenosis, thereby increasing systolic pulmonary arterial
pressure (SPAP) and decreasing functional capacity, simi-
larly to that observed in mitral stenosis or mitral pros-
thesis–patient mismatch.5-7
In the setting of FIMR, most studies comparing outcomes
after MVA or MVR have evaluated mitral valve hemody-
namics using resting Doppler echocardiography,8,9 which
often does not correlate with patient symptoms.10 Exercise
Doppler echocardiography represents amore reliablemethod
to evaluate mitral valve hemodynamic performance.10
The aim of this study was to compare both resting and ex-
ercise mitral valve hemodynamic performance in patients
undergoing surgical correction of FIMR. We designed this
study to compare the hemodynamic performance of MVA
with MVR and to identify the determinants of exercise
SPAP.MATERIALS AND METHODS
Patient Population
We retrospectively reviewed data prospectively collected on 194
consecutive patients with FIMR who underwent MVA or MVR combined
with coronary artery bypass grafting, at the Cardiovascular Department,
Ospedale ‘‘Papa Giovanni XXIII,’’ Bergamo Italy, between February
2005 and August 2009. Ethical approval was given by the local hospital
committee, and informed consent was obtained from all patients.
Indication for surgery was given during multidisciplinary meeting.
Because there is no clear consensus on the superiority of MVA or MVR
for severe FIMR, the choice between the 2 techniques was left to the
surgeon performing each operation. Two high-volume senior surgeons
(PF, MM)with special interest in mitral valve surgery and similar operative
outcomes were involved in all the surgical procedures. Both groups
received the same preoperative, operative, and postoperative care.
FIMR was defined by echocardiographic and coronary angiographic
findings using the following criteria: MR occurring more than 1 week after
myocardial infarction, as previously defined,11 1 or more left ventricular
(LV) segmental wall motion abnormalities, significant coronary artery dis-
ease in the territory supplying thewall motion abnormality, and structurally
normal mitral valve leaflets and chordae tendinae.11448 The Journal of Thoracic and Cardiovascular SurgExclusion criteria were as follows: acute ischemic mitral regurgitation
(MR); previous cardiac surgery or cardiac resynchronization therapy pro-
cedure; other significant valve disease (aortic, pulmonary, and tricuspid
valve); concomitant ventricular procedures; inadequate preoperative
echocardiogram; patients unable to exercise or unwilling to cooperate;
chronic lung disease; and patients with recurrent MR, defined as a
postoperative MR jet vena contracta width greater than 3 mm, at the
follow-up.
After the exclusion criteria were applied, the total population included
118 patients (MVA: n ¼ 72; MVR: n ¼ 46). There were 4 (3.4%) periop-
erative deaths (deaths within 30 days or before discharge from the index
hospitalization) without a significant difference between the patients
receiving MVR or MVA (MVR: n ¼ 1 [2.2%] vs MVA: n ¼ 3 [4.2%],
P ¼ .94).
The eligible population of 114 patients was prospectively contacted
from June 2010 to August 2010 to perform both baseline resting and exer-
cise Doppler echocardiography. These patients were then matched on a 1:1
basis in the following order: (1) indexed effective orifice area (IEOA), (2)
SPAP, and (3) LV ejection fraction (LVEF). We accepted a positive match
when the differences between 2 patients were less than 0.1 cm2/m2 in
IEOA, less than 5 mm Hg in SPAP, and less than 5% in LVEF. The final
matched population included 70 patients. All data regarding the whole un-
matched population are provided in Tables E1 to E3.
Data Collection and Outcome Measures
Coronary angiographic findings, preoperative clinical data, intraopera-
tive clinical data, postoperative clinical data, and Doppler echocardio-
graphic findings were prospectively collected in our institutional
database and retrospectively analyzed.
Surgical Technique
Both procedures were performed by median sternotomy. In the MVA
group, the ring sizer was selected by measuring the intercommissural dis-
tance of the mitral valve and positioned to cover the surface of the stretched
middle scallop of the anterior leaflet. A Carpentier-Edwards Physio ring
(Edwards Lifesciences, Irvine, Calif) undersized by 2 sizes was then in-
serted. In the MVR group, biological or mechanical prostheses were in-
serted with systematic preservation of the subvalvular apparatus. All
coronary vessels with significant stenosis on the preoperative angiogram
were grafted. Intraoperative transesophageal echocardiography was
routinely used.
Echocardiographic Protocol
Resting and exercise echocardiography studies were performed using
commercially available instruments (Vivid 7 imaging device; GE Health-
care, Little Chalfont, Buckinghamshire, United Kingdom). The echocar-
diographic and Doppler data were obtained at rest and at peak exercise
in digital format and stored on a workstation for offline analysis (EchoPAC,
GE Vingmed Ultrasound AS, Horten, Norway). Measurements were in-
dexed to body surface area, when necessary, and the Doppler tracings
were averaged from 3 to 5 beats.
According to the recommendations of the American Society of
Echocardiography,12 the following parameters were measured: LV end-
diastolic and end-systolic diameters; LVEF was measured using the modi-
fied biplane Simpson method; MR severity was assessed with the vena
contracta width. LV outflow tract (LVOT) area was determined as pD2/4,
where D is the diameter measured from a zoomed systolic freeze-frame
in the parasternal long-axis view. LV stroke volume (SV) was determined
by multiplying the LVOT area to the time integral of the outflow tract ve-
locity (pulsed-wave Doppler). Because LVOT area has been shown to
remain constant during exercise, the resting value was used to calculate
both rest and exercise SV. Cardiac output was calculated by multiplying
the SV and the heart rate.ery c August 2014
TABLE 1. Preoperative demographic and clinical data
All patients MVR MVA
P(n ¼ 70) (n ¼ 35) (n ¼ 35)
Demographic data
Male, n (%) 43 (61) 16 (45) 24 (68) .09
Age, y 64  5.4 65  3.8 64  5.1 .36
BSA (m2) 1.67  0.24 1.64  0.2 1.69  0.25 .33
Clinical data
Diabetes, n (%) 16 (23) 6 (17) 10 (28) .39
Systemic hypertension,
n (%)
48 (68) 23 (65) 25 (71) .8
Smoking history, n (%) 52 (74) 23 (65) 29 (82) .32
Dyslipidemia, n (%) 43 (61) 20 (57) 23 (65) .62
NYHA class III/IV, n (%) 29 (41) 10 (28) 19 (54) .05
Operative data
CPB time (min) 120  44 119  38 121  51 .91
ACC time (min) 90  31 86  22 93  38 .56
CABG (No. of grafts) 2.8  0.8 2.7  0.7 2.8  0.9 .6
Prosthesis type
Mechanical, n (%) 17 (49)
Bioprosthesis, n (%) 18 (51)
Values are mean  standard deviation (SD) when appropriate. ACC, Aortic cross-
clamp; BSA, body surface area; CABG, coronary artery bypass grafting; CPB, cardio-
pulmonary bypass;MVA, mitral valve annuloplasty;MVR, mitral valve replacement;
NYHA, New York Heart Association.
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The peak and mean transmitral pressure gradients were calculated using
the modified Bernoulli equation. Mitral valve effective orifice area (EOA)
was determined by the continuity equation using the SV divided by the in-
tegral of the mitral transvalvular velocity during diastole. The net atrioven-
tricular compliance was calculated from the valve EOA and mitral flow
E-wave downslope, as previously described.13,14 SPAP was calculated by
adding the systolic right ventricular pressure derived from the tricuspid
regurgitation to the estimated right atrial pressure.15
Exercise Study
A bicycle exercise test was performed in the semisupine position on a
dedicated tilting exercise table. The initial workload was set at 0 Watt, fol-
lowed by continuous increments of 10 to 25 Watt/min, depending on the
patient’s physical condition. Continuous electrocardiograms were re-
corded, and the blood pressure was measured at baseline, every 2 minutes,
and after each stage of exercise. Patients were encouraged to exercise until
exhaustion or the onset of symptoms. Doppler hemodynamic measure-
ments were obtained at peak exercise (ie, within the minute before and
the minute after the end of exercise).
Statistical Analysis
Quantitative variables are expressed as mean standard deviation. Dif-
ferences between preoperative and postoperative data were tested by
paired-samples t test after checking for normality of distribution. Categoric
variables are expressed as proportions and compared by chi-square or
Fisher exact test as appropriate. Resting and stress variables between pa-
tients who underwent MVA and MVR were compared by 2-way analysis
of variance for repeated measures. Associations between quantitative vari-
ables were evaluated by Pearson correlation test.
Independent determinants of exercise SPAP were investigated by
multiple linear regression analysis, entering variables displaying a cutoff
P value less than 1 at the univariate analysis. The type of surgery
(MVA or MVR) was included in the model as the dummy variable.
Area under the curve (AUC), sensitivity, and specificity for the
prediction of the occurrence of exercise pulmonary hypertension (PH)
were determined for various cutoff values of resting echocardiographic
parameters with receiver operating characteristic curves.
Interobserver variability was evaluated as the standard difference of the
differences in each measurement, calculated by 2 independent observers
for 10 different patients, expressed as the percent of mean (coefficient of
variation) and 5% of the mean. Intraobserver variability, derived from
repeated calculations 1 month apart, was 6%. All statistical analysis was
performed with SPSS 15.0 (SPSS Inc, Chicago, Ill).RESULTS
Patients’ Characteristics and Operative Data
Preoperative demographic, clinical, and operative data of
the matched population are presented in Table 1. There was
no significant difference between the 2 groups in terms of
gender distribution, age, New York Heart Association class,
and cardiovascular risk profile.
MVA was performed using Carpentier-Edwards Physio
Ring size 26 mm in 6 patients (17%), 28 mm in 18 patients
(51%), 30 mm in 10 patients (29%), and 32 mm in 1 patient
(3%). In the MVR group, 8 patients (23%) received a
Carpentier-Edwards bioprosthesis size 27, 9 patients
received size 29 (26%), and 1 patient received size 31
(3%). A mechanical St Jude Medical, Inc (St Paul, Minn)
valve size 27 was used in 3 patients (8%), size 29 wasThe Journal of Thoracic and Caused in 9 patients (26%), and size 25 was used in 1 patient
(3%); a Carbomedics (Sorin Group, Milan, Italy) size 27
was used in 3 patients (8%) and size 29 was used in 1
patient (3%). All patients underwent coronary artery
bypass grafting with no significant difference in terms of
number of grafted vessels or procedural time in the 2 groups
(Table 1).
Preoperative and Postoperative
Doppler-Echocardiographic Data
Themedian follow-up (ie, time between surgery and exer-
cise stress echocardiography) was 30 months (interquartile
range, 21-46 months) and was statistically significantly
different between the 2 groups (MVA: 37 months, interquar-
tile range, 25-52 months; MVR: 24 months, interquartile
range, 14-38 months; P ¼ .01).
In the MVR group, preoperative MR was severe in 31
patients (88%) and moderate in 4 patients (11%); in the
MVA group, the MR was severe in 30 patients (86%) and
moderate in 5 patients (14%). At the time of exercise
echocardiography, New York Heart Association III-IV
was 14% in the MVR group and 31% in the MVA group,
with no statistical difference (P ¼ .15). The preoperative
severity of MR was similar in the MVA and MVR groups
(vena contracta width: 0.7  0.01 cm vs 0.7  0.02 cm,
respectively, P ¼ .9; Table 2).
LV dimension significantly decreased within groups after
surgery, with no significant difference between the 2
groups. There were no concomitant significant changes in
LVEF and heart rate.rdiovascular Surgery c Volume 148, Number 2 449
TABLE 2. Preoperative and postoperative Doppler-echocardiographic data
Variables
MVR (n ¼ 35) MVA (n ¼ 35) ANOVA P value
Preoperative Postoperative Preoperative Postoperative Within Between
LV geometry
LVED diameter, mm 61  6 56  5 62.  6 56.  6 .001 .3
LVES diameter, mm 48  7 42  7 52  13 45  6 .001 .3
Indexed LVED diameter, mm/m2 36  3 33  6 36  6 32  2 .001 .9
Indexed LVES diameter, mm/m2 26  5 25  6 30  5 26  3 .003 .6
LV function
LVEF,% 41  9 41  6 36  8 40  4 .05 .1
Heart rate, beats/min 70  15 71  8 69  6 73  12 .1 .4
Cardiac output, L/min 4.5  1 5  1 4  0.5 5  1 .08 .6
Cardiac index, L/min/m2 1.8  1.3 3  0.8 1.7  1.3 2.8  0.6 .001 .9
Mitral valve hemodynamics
Peak gradient, mm Hg 4  0.7 10  4 3.6  0.8 9  3.4 .001 .9
Mean gradient, mm Hg 1.6  0.2 5  2 1.5  0.2 4  1.3 .001 .8
SPAP, mm Hg 38  13 33  6 40  6 37  9 .06 .3
MR jet vena contracta, cm 0.7  0.02 — 0.7  0.01 NA .9
Values are mean  SD when appropriate. ANOVA, Analysis of variance; LV, left ventricular; LVED, left ventricular end diastolic; LVEF, left ventricular ejection fraction;
LVES, left ventricular end systolic;MR,mitral regurgitation;MVA,mitral valve annuloplasty;MVR,mitral valve replacement;NA, not available; SPAP, systolic pulmonary arterial
pressure.
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gradients increased, with no significant difference between
the 2 groups. Preoperative SPAP was 40 mm Hg or more in
26 patients (37%), with no significant difference between
the 2 groups (MVA group: n ¼ 14, 40% vs MVR group:
n ¼ 12, 34%, P ¼ .64).
Comparison of Postoperative Resting and Exercise
Echocardiographic Data
Percentage of age-predicted maximal heart rate, maximal
workload, peak systolic blood pressure, and heart rate wereTABLE 3. Exercise Doppler-echocardiographic data
MVR
Rest
Exercise capacity
Heart rate, beats/min 71  8
Percentage of age-predicted heart rate,% —
Systolic blood pressure, mm Hg 133  14
Workload, Watt —
LV function
LVEF,% 41  6
Net atrioventricular compliance, mL/mm Hg 4.5  5
Cardiac output, L/min 5  1
Cardiac index, L/min/m2 3  0.8
Mitral valve hemodynamics
EOA, cm2 2  0.4
IEOA, cm2/m2 1.3  0.3
Mitral peak gradient, mm Hg 10  4
Mitral mean gradient, mm Hg 5  2
SPAP, mm Hg 33  6
MR jet vena contracta width, cm —
Values are mean SDwhen appropriate. EOA, Effective orifice area; IEOA, indexed effecti
regurgitation;MVA,mitral valve annuloplasty;MVR,mitral valve replacement; SPAP, systo
450 The Journal of Thoracic and Cardiovascular Surgnot significantly different between the MVA and MVR
groups (Table 3). At rest, none of the postoperative Doppler
echocardiographic variables, including IEOA, were
different between the MVA and MVR groups (Table 3).
LVEF significantly increased during exercise, with no
difference between the 2 groups. The exercise-induced in-
crease in cardiac output and cardiac index was significant
in both groups (P< .01 for all), but higher in the MVR
group (Table 3, P ¼ .014 for interaction MVA/MVR, for
both parameters). Exercise net compliance significantly
decreased, with no differences between the 2 groups.(n ¼ 35) MVA (n ¼ 35)
Exercise Rest Exercise
114  13* 73  12 124  14*
74  10 — 79  9
174  14* 136  12 174  14*
94  17 — 95  21
49  7* 39  4 48  7*
2.4  0.5* 4.1  3.1 2.2  0.7*
9  1.5* 5  1 8  1.5*,y
5.6  1.2* 2.8  0.6 4.7  0.9*,y
2.3  0.4* 2  0.6 1.9  0.4y
1.4  0.2* 1.2  0.3 1.2  0.2y
15.6  8.2* 9  3 19.5  7*
9.3  4* 4  1.3 11.2  4*
42  6* 37  9 55  12*,y
— 0.1  0.1 0.2  0.2
ve orifice area; LV, left ventricular; LVEF, left ventricular ejection fraction;MR,mitral
lic pulmonary arterial pressure. *P<.05 (rest vs exercise). yP<.05 (MVAvs MVR).
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FIGURE 1. Absolute (A) and relative (B) exercise-induced changes in
SPAP according to surgical technique (MVA vs MVR). MV, Mitral valve;
SPAP, systolic pulmonary arterial pressure.
FIGURE 2. Mitral valve opening reserve assessed as the individual
exercise-induced changes in IEOA for MVA (A) and MVR (B) groups.
EOA, Effective orifice area; SD, standard deviation.
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pressure gradients were statistically similar in both groups
(Table 3). Exercise SPAP was significantly higher in the
MVA group compared with the MVR group (55  12 mm
Hg vs 42  6 mm Hg, P ¼ .0001, respectively; Table 3).
Absolute and relative exercise-induced increases in SPAP
were significantly higher in the MVA group (Figure 1).
During exercise, EOA and IEOA increased significantly
only in patients receiving MVR (MVR: þ0.23  0.04
cm2 vs MVA: 0.1  0.09 cm2, P ¼ .001, for EOA;
MVR: þ0.14  0.03 cm2/m2 vs MVA: 0.04  0.07
cm2/m2, P ¼ .03, for IEOA, Figure 2). Exercise SPAP
was inversely correlated with exercise IEOA (r ¼ 0.45;
P ¼ .01, Figure 3).
At the multivariable analysis, MVA, exercise IEOA, and
resting peak transmitral pressure gradient were independent
predictors of exercise SPAP (Table 4).
By using receiver operating characteristic curve analysis,
the best resting echocardiographic predictors of theThe Journal of Thoracic and Caoccurrence of exercise PH were IEOA (AUC ¼ 0.77),
mean pressure gradient (AUC ¼ 0.70), and SPAP
(AUC ¼ 0.74). The best cutoff value for resting IEOA
was 1.1 cm2/m2 (sensitivity ¼ 79%, specificity ¼ 62%).DISCUSSION
To the best of our knowledge, this study is the first
to compare resting and exercise hemodynamic perfor-
mance of MVA and MVR in patients with FIMR. The
main finding of the study is that compared with a
matched group of MVR, patients receiving a successful
MVA (ie, without persistent or recurrent significant
MR) had worse mitral hemodynamic performance
during exercise, resulting in higher SPAP. MVA was
associated with an absence of mitral opening reserve
and in approximately 29% of exercise PH. In multi-
variate analysis, reduced IEOA, resting peak gradients,
and MVA were independent predictors of postoperative
elevated SPAP.rdiovascular Surgery c Volume 148, Number 2 451
FIGURE 3. Relationship between exercise SPAP and IEOA during
exercise. IEOA, Indexed effective orifice area; SPAP, systolic pulmonary
arterial pressure.
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The complex pathophysiologic mechanism underlying
FIMR is related to the outward displacement of the poste-
rior and anterior papillary muscles as a result of LV remod-
eling, which causes annular dilatation, leaflet tethering, and
mitral valve deformation, eventually leading to a miscoap-
tation with central or posterior regurgitation jet. The
displacement, causing separation of the papillary muscles,
puts both the second-order and the free-edge first-order
chordae under tension, reducing the flexibility of most
part of the anterior leaflet and impairing its mobility.16
MVA, by insertion of a ring, fixes the posterior leaflet and
further restricts its opening.17 The mitral valve motion
may become more resistant to transvalvular flow with
consequent restriction of its opening. In addition, the ante-
rior displacement of the posterior annulus caused by the
prosthetic ring further increases the subvalvular tethering,
leading to a reduction of the mitral valve opening in term
of functional reserve.18 These pathophysiologic conse-
quences explain the decrease in the mitral valve area and
the transmitral gradient increment, which worsens signifi-
cantly after exercise.6
Conversely, in patients with MVR, the increase in trans-
valvular flow rate during exercise may lead to a higher EOA
than at rest. These dynamic improvements, combined
with the exercise-induced changes in atrioventricularTABLE 4. Independent determinants of exercise systolic pulmonary
arterial pressure
b SE P value
MVA 0.4 2.1 .0001
Exercise IEOA 0.34 4 .001
Resting mitral peak gradient 0.3 0.3 .0001
IEOA, Indexed effective orifice area; MVA, mitral valve annuloplasty; SE, standard
error.
452 The Journal of Thoracic and Cardiovascular Surgcompliance, contribute to the transprosthetic gradient
reduction limiting, as a consequence, the increase in SPAP.Comparison With Previous Studies
In patients undergoing MVA, we previously found a sig-
nificant reduction of resting and exercise EOA and IEOA,
along with increased mitral gradients and SPAP.5 Kubota
and colleagues6 reported a persistent subvalvular leaflet
tethering as a frequent cause of postoperative functional
mitral stenosis, with a significant exercise-induced hemody-
namic worsening symptom.
In the current study, we found that during exercise,
despite substantial increase in cardiac output, cardiac index,
and transmitral flow rate, the EOA did not increase in pa-
tients with MVA, resulting in a significant increase in trans-
valvular pressure gradients. Patients with MVR also
developed higher exercise cardiac output and cardiac index,
but the concomitant marked improvement in EOA, likely
because of the presence of mitral valve opening reserve,
led to less increase in mean and peak transvalvular pressure
gradients. These observations are consistent with previous
studies19 and reinforce the concept that after MVA, the
annular reduction does not relieve subvalvular tethering
and further impairs mitral valve hemodynamics.
Different from other studies,13,14 the current study found
no significant relationship from rest to exercise between
compliance and SPAP. However, we focused only on
patients undergoing operation for FIMR, whereas the
previous series mainly included patients with mitral
stenosis and preserved LVEF. There was also a significant
decrease of compliance during exercise, although no
significant differences were observed between MVA and
MVR cases.
As shown by Li and colleagues,20 IEOAwas, in multivar-
iate analysis, the strongest independent parameter associ-
ated with exercise SPAP, confirming its role as main
factor influencing valve hemodynamics and predicting
adverse outcomes.21Clinical Implications
In line with other findings,6 the current study showed that
patients with MVA may have a reduced EOA, IEOA, and
lack in mitral opening reserve, with a consequent high
rate of postoperative exercise PH. Consequently, the
negative effect of MVA seems related to the ring itself,
being unable to correct the subvalvular tethering and, in
some cases, worsening it. In this regard, the best approach
would be to perform less restrictive MVA, targeting the
reduction of the subvalvular tethering to improve the
postoperative hemodynamic performance. However, this
potential advantage would likely be offset by a substantial
rate of persistent/recurrent MR, which is known to be
associated with poor prognosis.22ery c August 2014
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subvalvular tethering, would lead to better hemodynamic
performance under exercise. Until the ongoing National In-
stitutes of Health–funded clinical trial is completed, the sur-
gical strategy in patients with FIMR remains controversial
and partially guided by the surgeon’s expertise and center
experience.
Study Limitations
This study reports retrospective data and thus is subject to
all the limitations inherent to this design. We did not mea-
sure oxygen extraction at rest and during exercise to exclude
patients’ physical conditioning as a cause of the differences
in pulmonary artery pressures. However, this should not
change the main finding of the present study. The choice
of MVA or MVR, which was left to the surgeon performing
each operation, may represent a bias in the distribution of
baseline characteristics between groups. Preoperative
data, such as annular size, tenting height, or tenting area,
were available only in a small subset of patients, precluding
a meaningful conclusion. The postoperative echocardio-
graphic examinations were not performed at a similar inter-
val of time from surgery. However, it is unlikely that this
difference had an impact on exercise mitral valve hemody-
namic performance. Mechanical and biological prostheses
were included in the analysis, but prosthesis opening is
not influenced by the subvalvular apparatus. Finally, the re-
sults of our study cannot be automatically applied to the
newer rings specifically designed to correct FIMR.
CONCLUSIONS
In patients with FIMR, MVA may result in worse hemo-
dynamic performance than MVR, particularly during exer-
cise. MVA was associated with poor exercise mitral
hemodynamic performance, lack of mitral valve opening
reserve, and markedly elevated postoperative exercise
SPAP compared with MVR. These results confirm that the
surgical treatment of FIMR is suboptimal, suggesting that
procedures targeting the correction of the underlying path-
ophysiologic mechanisms should be encouraged. Nonethe-
less, further studies are needed to confirm our findings and
to determine the potential relationship between the postop-
erative elevated SPAP reported in the MVA group and the
outcome of these patients.
The authors thank Professor Luc A. Pierard (University of
Liege, Belgium).
References
1. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral
regurgitation: long-term outcome and prognostic implications with quantitative
Doppler assessment. Circulation. 2001;103:1759-64.The Journal of Thoracic and Ca2. Mitesh VB, Subodh V, Vivek R. Surgical management of ischemic mitral regur-
gitation. Circulation. 2009;120:1287-93.
3. Lorusso R, Gelsomino S, Vizzardi E, D’Aloia A, De Cicco G, Fabiana Luc F,
et al., and the ISTIMIR Investigators. Mitral valve repair or replacement for
ischemic mitral regurgitation? The Italian study on the treatment of ischemic
mitral regurgitation (ISTIMIR). J Thorac Cardiovasc Surg. 2013;145:128-39.
4. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate term outcome of
mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998;
115:381-6.
5. Magne J, Senechal M, Mathieu P, Dumesnil JG, Dagenais F, Pibarot P. Restric-
tive annuloplasty for ischemic mitral regurgitation may induce functional mitral
stenosis. J Am Coll Cardiol. 2008;51:1692-701.
6. Kubota K, Otsuji Y, Ueno T, Koriyama C, Levine RA, Sakata R, et al. Functional
mitral stenosis after surgical annuloplasty for ischemic mitral regurgitation:
importance of subvalvular tethering in the mechanism and dynamic deterioration
during exertion. J Thorac Cardiovasc Surg. 2010;140:617-23.
7. Magne J, Mathieu P, Dusmenil JG, Tanne D, Dagenais F, Doyle D, et al. Impact
of prosthesis-patient mismatch on survival after mitral valve replacement. Circu-
lation. 2007;115:1417-25.
8. Gillinov M. Is ischemic mitral regurgitation an indication for surgical repair or
replacement? Heart Fail Rev. 2006;11:231-9.
9. Vassileva CM, Boley T, Markwell S, Hazelrigg S. Meta-analysis of short-term
and long-term survival following repair versus replacement for ischemic mitral
regurgitation. Eur J Cardiothorac Surg. 2011;39:295-303.
10. Picano E, Pibarot P, Lancellotti P, Monin JL, Bonow RO. The emerging role of
exercise testing and stress echocardiography in valvular heart disease. J Am
Coll Cardiol. 2009;54:2251-60.
11. Borger MA, Alam A, Murphy P, Doenst T, Tirone ED. Chronic ischemic mitral
regurgitation: repair, replace or rethink? Ann Thorac Surg. 2006;81:1153-61.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.
Recommendations for chamber quantification: a report from the American Soci-
ety of Echocardiography’s Guidelines and Standards Committee and the Cham-
ber Quantification Writing Group, developed in conjunction with the European
Association of Echocardiography, a branch of the European Society of Cardiol-
ogy. Chamber Quantification Writing Group; American Society of Echocardiog-
raphy’s Guidelines and Standards Committee; European Association of
Echocardiography. J Am Soc Echocardiogr. 2005;18:1440-63.
13. Li M, Dery JP, Dusmenil JG, Boudreault JR, Jobin J, Pibarot P. Usefulness of
measuring net atrioventricular compliance by Doppler echocardiography in pa-
tients with mitral stenosis. Am J Cardiol. 2005;96:432-5.
14. Schwammenthal E, Vered Z, Agranat O, Kaplinsky E, Rabinowitz B,
Feinberg MS. Impact of atrioventricular compliance on pulmonary arterial pres-
sure in mitral stenosis: an exercise echocardiographic study. Circulation. 2000;
102:2378-84.
15. Pepi M, Tamborini G, Galli C, Barbier P, Doria E, Berti M, et al. A new formula
for echo-Doppler estimation of right ventricular systolic pressure. J Am Soc
Echocardiogr. 1994;7:20-6.
16. Yellin EL, Peskin C, Yoran C, Koenigsberg M, Matsumoto M, Laniado S, et al.
Mechanisms of mitral valve motion during diastole. Am J Physiol Heart Circ
Physiol. 1981;241:H389-400.
17. Green GR, Dagum P, Glasson JR, Nistal JF, Daughters GT, Ingels NB, et al.
Restricted posterior leaflet motion after mitral ring annuloplasty. Ann Thorac
Surg. 1999;68:2100-6.
18. Zhu F, Otsuji Y, Yotsumoto G, Yuasa T, Ueno T, Yu B, et al. Mechanism of persis-
tent ischemic mitral regurgitation after annuloplasty: importance of augmented
posterior mitral leaflet tethering. Circulation. 2005;112:I-396-401.
19. Hobson NA, Wilkinson GAL, Cooper GJ, Wheeldom NM, Lynch J. Hemody-
namic assessment of mitral mechanical prostheses under high flow conditions:
Comparison between dynamic exercise and dobutamine stress. J Heart Valve
Dis. 2006;15:87-91.
20. Li M, Dumesnil JG, Mathieu P, Pibarot P. Impact of valve prosthesis-patient
mismatch on pulmonary arterial pressure after mitral valve replacement. J Am
Coll Cardiol. 2005;45:1034-40.
21. Pibarot P, Dusmenil JG. Prosthesis-patient mismatch: definition, clinical impact,
and prevention. Heart. 2006;92:1022-91.
22. Hung J, Papakostas L, Tahta SA, Hrady BG, Bollen B, Duran C, et al. Mechanism
of recurrent ischemic mitral regurgitation after annuloplasty: continued LV
remodeling as a moving target. Circulation. 2004;110(Suppl II):II-85-90.rdiovascular Surgery c Volume 148, Number 2 453
TABLE E1. Preoperative demographic and clinical data
All patients MVR MVA
P(n ¼ 114) (n ¼ 57) (n ¼ 57)
Demographic data
Male, n (%) 67 (58.8) 31 (54.4) 36 (63.2) .44
Age, y 65.1  5.7 66. 5  5.7 63.7  5.4 .007
BSA (m2) 1.71  0.18 1.68  0.19 1.74  0.17 .07
Clinical data
Diabetes, n (%) 25 (21.9) 14 (24.6) 11 (19.3) .65
Systemic hypertension,
n (%)
70 (61.4) 39 (68.4) 31 (54.4) .12
Smoking history, n (%) 70 (61.4) 33 (57.9) 37 (64.9) .56
Dyslipidemia, n (%) 71 (62.3) 40 (70.2) 31 (54.4) .12
NYHA class III/IV,
n (%)
62 (54.4) 26 (54.4) 26 (54.4) 1
Operative data
CPB time (min) 106  35 106  32 106  38 .96
ACC time (min) 86  23 84  17 87  27 .44
CABG (No. of grafts) 2.6  0.8 2.7  0.70 .61
Prosthesis type
Mechanical, n (%) 26 (48.1) 26 (48.1)
Bioprosthesis, n (%) 28 (51.9) 28 (51.9)
Values are mean SDwhen appropriate. ACC,Aortic crossclamp; BSA, body surface
area; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; MVA,
mitral valve annuloplasty; MVR, mitral valve replacement; NYHA, New York Heart
Association.
TABLE E2. Preoperative and postoperative Doppler-echocardiographic data
Variables
MVR (n ¼ 57) MVA (n ¼ 57) ANOVA P value
Preoperative Postoperative Preoperative Postoperative Within Between
LV geometry
LVED diameter, mm 60.1  4.8 56.4  3.7 59.4  9 53.9  4.5 .001 .08
LVES diameter, mm 47.4  6.6 41.7  5.2 49.5  11.6 43.5  4.4 .001 .08
Indexed LVED diameter, mm/m2 36  3.9 34  3.2 36.1  4.9 33.2  2.1 .001 .62
Indexed LVES diameter, mm/m2 27.1  4.9 27.4  3 30.5  5 27.4  3 .001 .001
LV function
LVEF,% 39.2  7.5 42.8  4.6 36.6  7.4 39.8  3.8 .001 .02
Heart rate, beats/min 70  12 71  6 71  5 72  8 .35 .26
Cardiac output, L/min 4.4  0.6 5  0.8 4.3  0.4 4.3  0.7 .001 .001
Cardiac index, L/min/m2 2.7  0.5 3  0.5 2.5  0.3 2.5  0.3 .001 .001
Mitral valve hemodynamics
Peak gradient, mm Hg 3.5  0.7 8  3.3 3.4  0.8 8.5  2.1 .001 .47
Mean gradient, mm Hg 1.6  0.2 4  1.3 1.6  0.3 4.6  1.3 .001 .04
SPAP, mm Hg 38.2  9.7 31.8  5.4 40  9.2 27.2  6 .001 .003
MR jet vena contracta, cm 0.7  0.07 — 0.72  0.08 — NA .37
Values are mean SDwhen appropriate. LV, Left ventricular; LVED, left ventricular end diastolic; LVES, left ventricular end systolic;MR,mitral regurgitation;NA, not available;
SPAP, systolic pulmonary arterial pressure; MVA, mitral valve annuloplasty; MVR, mitral valve replacement; ANOVA, Analysis of variance; LVEF, left ventricular ejection
fraction.
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TABLE E3. Exercise Doppler-echocardiographic data
MVR (n ¼ 57) MVA (n ¼ 57)
Rest Exercise Rest Exercise
Exercise capacity
Heart rate, beats/min 72  8 109  15* 74  10 122  15*,y
Percentage of age-predicted heart rate,% — 72  6 78  8
Systolic blood pressure, mm Hg 132  11 169 13* 136  12 134  14*
Workload, Watt — 95  14 96  19
LV function
LVEF,% 42  6 48  9* 40  4y 49  6.1*
Net atrioventricular compliance, mL/mm Hg 4  4 2.5  0.5* 3.6  2.6 2.2  0.6*,y
Cardiac output, L/min 5.1  1 8.8  1.4* 4.6  1y 7.6 1.3*,y
Cardiac index, L/min/m2 3.1  0.9 5.6  1.3* 2.8  0.7 4.7 1*
Mitral valve hemodynamics
EOA, cm2 2  0.5 2.2  0.4* 1.8  0.5y 1.8  0.4y
IEOA, cm2/m2 1.3  0.3 1.5  0.3* 1.1  0.3y 1.1.  0.2y
Mitral peak gradient, mm Hg 8.4  4 15.6  7.9* 8.6  2.6 19.7  6.6*,y
Mitral mean gradient, mm Hg 4.5  1.9 9.2  3.8* 4.5  1.3 11  3.7*,y
SPAP, mm Hg 32  7 43  11* 38  7y 55  11*,y
MR jet vena contracta width, cm — — 0.2  0.2 0.3  0.2
Values are mean SDwhen appropriate. EOA, Effective orifice area; IEOA, indexed effective orifice area; LVEF, left ventricular ejection fraction;MR,mitral regurgitation; SPAP,
systolic pulmonary arterial pressure;MVA, mitral valve annuloplasty;MVR, mitral valve replacement; LV, left ventricular. *P<.05 (rest vs exercise). yP<.05 (MVAvs MVR).
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